Insulin Resistance Clinical Trial
— M-PCOSOfficial title:
Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome
Verified date | April 2015 |
Source | Tel Aviv University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ethics Commission |
Study type | Interventional |
In obese women with polycystic ovary syndrome (PCOS), weight loss improves insulin resistance and hyperandrogenism, resulting in improvement of clinical symptoms. Weight loss is not required in lean PCOS patients; nevertheless, the influence of meal timing and composition on glucose metabolism and hyperandrogenism may have clinical value. In this study the investigators investigate the effects of two isocaloric diets with different meal timing distribution on insulin resistance and hyperandrogenism in lean PCOS patients.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | June 2015 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Subjects =18 and =45 years of age 2. Lean women with PCOS (BMI: = 25 kg/m2) 3. Signed informed consent 4. Exclusion of late-onset adrenal hyperplasia by a fasting serum 17- hydroxy progesterone concentration below 200 ng/dl. 5. Acceptable health based on interview, medical history, physical examination, and laboratory tests (SMA20 and CBC). 6. Not dieting and no change in body weight >10 lb = 4.5 kg within the last 6 months 7. Stable physical activity pattern during the three months immediately preceding study initiation 8. Hyperandrogenemia (elevated free testosterone). 9. Normal liver and kidney function 10. Fasting blood glucose <110 mg/dl. 11. No metabolic disease 12. Usually wakes up between 05:00 and 07:00 and goes to sleep between 22:00 and 24:00. 13. Normal TSH and FT4 levels and serum prolactin 14. Acceptable health based on interview, medical history, physical examination, and laboratory tests Exclusion Criteria: 1. Diabetes mellitus diagnosed by fasting glucose or a 2-hour OGTT, or fasting glucose > 110 mg/dl 2. Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, malignant disease (other than skin cancer). 3. Current use of oral contraceptives 4. Serum creatinine level > 1.5 mg/dl 5. Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase and/or aspartate 6. Any physiologic or mechanical problems preventing dietary adherence 7. Pregnant or lactating 8. Participating in another dietary program or use of weight-loss medications 9. Documented or suspected history (within one year) of illicit drug abuse or alcoholism. 10. Use of psychotropic or anoretic medication during the month immediately prior to study onset 11. Night or rotating shift work 12. Jet lag during the 2 week period immediately prior to study onset |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Israel | Daniela Jakubowicz | Holon | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Tel Aviv University |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | hyperandrogenism | Androgens will be evaluate at baseline and after one of two isocaloric diet that differe in meal timing distribution | 90 days | No |
Secondary | glucose metabolism | Glucose metabolism will be evaluated at baseline and after one of two isocaloric diets that differ in meal timing distribution | 90 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03383822 -
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT04203238 -
Potato Research for Enhancing Metabolic Outcomes
|
N/A | |
Recruiting |
NCT03658564 -
Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance
|
N/A | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03627104 -
Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT01809288 -
Identifying Risk for Diabetes and Heart Disease in Women
|
||
Completed |
NCT04642482 -
Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A | |
Withdrawn |
NCT04741204 -
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
|
Phase 4 |